See more : Morgan Stanley (MS-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Odonate Therapeutics, Inc. (ODT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Odonate Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dawning Information Industry Co., Ltd. (603019.SS) Income Statement Analysis – Financial Results
- Axsome Therapeutics, Inc. (AXSM) Income Statement Analysis – Financial Results
- Mission Valley Bancorp (MVLY) Income Statement Analysis – Financial Results
- Overseas Chinese Town (Asia) Holdings Limited (3366.HK) Income Statement Analysis – Financial Results
- Heartland Financial USA, Inc. (HTLFP) Income Statement Analysis – Financial Results
Odonate Therapeutics, Inc. (ODT)
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 117.04M | 104.03M | 79.95M | 27.90M | 2.62M | 0.00 |
| General & Administrative | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -316.00K |
| Operating Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | -158.00K |
| Cost & Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | 158.00K |
| Interest Income | 0.00 | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 445.00K | 381.00K | 350.00K | 20.00K | 22.82K | 0.00 |
| EBITDA | -125.91M | -111.44M | -88.61M | -32.72M | -3.09M | -158.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -127.43M | -114.93M | -90.76M | -32.74M | -3.09M | -158.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Net Income | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| EPS Diluted | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| Weighted Avg Shares Out | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
| Weighted Avg Shares Out (Dil) | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been...
Odonate Therapeutics Stock (ODT): Why The Price Plummeted Today
The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) fell by over 17% during intraday trading today. This is why it happened.
SHAREHOLDER ALERT: Odonate Therapeutics, Inc. (ODT) Officers and Directors Under Investigation for Possible False Statements to Investors
SAN FRANCISCO, Aug. 13, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Odonate Therapeutics, Inc. (NASDAQ: ODT) relating to possible false statements to investors regarding its only product, tesetaxel, a...
The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $ODT #investors--The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the biggest biopharma movers Tuesday. Odonate Gains On Institutional Stake: Shares of Odonate,...
ODT Stock Price Increases Over 20% Pre-Market: Details
The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) increased by over 20% pre-market. These are some details you should know.
7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.
3 Net Current Asset Value Stock Picks
There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe they can gain from these kinds of investments after the market has reappraised the share prices to near or above the liquidation...
Odonate Therapeutics (ODT) Enters Oversold Territory
Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Odonate Therapeutics: Lessons Learned
Odonate shut down its Tesetaxel program - and the company itself - without any warning.
Source: https://incomestatements.info
Category: Stock Reports